CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Pfizer (PFE), Valneva (VALN) Lyme Vaccine Moves to EMA Review Despite Phase 3 Caveat

RegulatoryPositive
AI Analysis

Summary

Pfizer and Valneva's Lyme disease vaccine candidate has advanced to European Medicines Agency (EMA) review, despite Phase 3 trial caveats mentioned in the coverage.

Outcome Details

Lyme vaccine candidate moves to EMA review

Importance:7/10
Sentiment:
0.50
Lyme vaccineEMA reviewPhase 3PfizerValneva
Related Companies

Read the original article

Published by yahoo_finance on September 15, 2026 4:21 PM

Read Original